Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11456, a tocilizumab biosimilar candidate, successfully met the primary and secondary endpoints in two consecutively conducted clinical trials. For more information, please visit the Fresenius Kabi website.

Temsirolimus Injection, a drug used to treat advanced renal cell carcinoma, is now available from Fresenius Kabi in the United States. This is the newest addition to the company’s portfolio of generic IV oncology products - the largest such portfolio in the U.S.

Susanne Zeidler and Dr. Frank Appel proposed for election to the Supervisory Board of Fresenius Management SE

Michael Sen (52) will become the new Chief Executive Officer of Fresenius Kabi AG. The Supervisory Board of Fresenius Management SE has unanimously appointed him to the Management Board of Fresenius effective on April 12, 2021. He succeeds Mats Henriksson (53), who is leaving the company due to different views on Fresenius Kabi’s future direction.

Michael Sen was a member of the Management Board of Siemens AG from April 2017 to March 2020, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. Prior to that, from 2015 to 2017, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Michael Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin. After graduation, he took on various management roles at Siemens starting in 1996 in both operating businesses and central divisions. From 2008 to 2015, he was a member of the Executive Team and CFO of Siemens Healthcare.

Mats Henriksson joined the Management Board of Fresenius Kabi on September 1, 1999. From 2001 to February 2012, he was responsible for the company’s Asia-Pacific region. From March 1, 2012, he served as Deputy Chairman of the Management Board of Fresenius Kabi, and on January 1, 2013 was appointed Chairman of the Management Board of Fresenius Kabi.

Dr. Gerd Krick, Chairman of the Supervisory Board of Fresenius, said: "Mats Henriksson played a major role in the development of Fresenius Kabi from the very beginning. From the acquisition and integration of Pharmacia & Upjohn, which became Fresenius Kabi in 1999, to the very successful expansion in Asia under his responsibility and the entry into the promising biosimilars business, he has made numerous important contributions to the growth of this Fresenius business segment. Mats Henriksson is handing over a well-managed business to his successor. On behalf of the entire Supervisory Board, I would like to thank him most sincerely. I wish him every success and the best for his future."

Wolfgang Kirsch, the designated Chairman of the Supervisory Board of Fresenius, said: "Fresenius has developed extremely dynamically and successfully over the past years, from a medium-sized company to a global healthcare group with sales of more than €36 billion today. With the recently presented growth strategy, the Management Board, under the proven leadership of Stephan Sturm, is setting the course for the company's sustained, successful further development. My colleagues on the Supervisory Board and I fully support this strategy, including the announced, ongoing and open review of the Group structure. Michael Sen is an experienced manager in the healthcare sector who complements our team very well. The Management Board of Fresenius is ideally positioned to successfully implement the strategy in the coming years and to continue Fresenius' growth story."

Stephan Sturm, CEO of Fresenius, said: "I have worked closely, trustfully and successfully with Mats Henriksson for many years. I thank him, and I personally wish him all the best. At the same time, I look forward to working with Michael Sen in the future. Fresenius Kabi's business addresses several attractive growth areas in medicine. It is and will remain of central strategic importance for our healthcare group. Together, we will work in the coming years to make this company even stronger – for the benefit of the growing number of patients who depend on our important drugs and products and for our shareholders."

Michael Sen said: "Fresenius Kabi is committed to improving the quality of life of patients around the world. In my future role, I would like to continue to put patient well-being at the center of everything we do and play my part in continuing the company's successful development. I am very much looking forward to working with Stephan Sturm and the entire team on the Management Board of Fresenius, and of course with my more than 40,000 new colleagues at Fresenius Kabi worldwide. With courage, dedication and creativity, we can and will still achieve a lot together."

The Supervisory Board of Fresenius Management SE also unanimously resolved to propose Susanne Zeidler (60), Chief Financial Officer of Deutsche Beteiligungs AG (DBAG) since November 2012, and Dr. Frank Appel (59), Chief Executive Officer of Deutsche Post DHL Group since February 2008, for election to the Supervisory Board of Fresenius Management SE.

Susanne Zeidler worked for the auditing and consulting firm KPMG between 1990 and 2010. Lastly, as a partner, she was responsible for KPMG's business with foundations and other non-profit organizations, which, as a qualified auditor and tax advisor, she had helped to establish from 2006 onwards. Prior to that, from 1990 to 1999, she was involved in the valuations of medium-sized and listed companies in various industries, and between 2000 and 2005 was the partner responsible for KPMG's internal audit review. Before joining the Management Board of DBAG, Susanne Zeidler was Managing Director at the headquarters of the international charity organization "Kirche in Not" ("Aid to the Church") from the beginning of 2011.

Dr. Frank Appel has worked for Deutsche Post DHL Group since 2000, initially as Managing Director Corporate Development, and from 2002 as Board Member responsible for Global Business Services and Key Account Management Global Customer Solutions. In 2005, he was responsible for the acquisition and integration of the British logistics company Exel. In February 2008, he was appointed Chief Executive Officer. A graduate chemist with a PhD in neurobiology, he began his professional career in 1993 at the management consultancy McKinsey, where he became a member of German Business Management in 1999 before joining Deutsche Post DHL Group.

As already announced in October 2020, Dr. Gerd Krick (82) will leave the Supervisory Boards of Fresenius Management SE and the listed Fresenius SE & Co. KGaA when his term ends at the close of the Annual General Meeting in May 2021. Wolfgang Kirsch (65), a member of the Supervisory Board of Fresenius Management SE since January 1, 2020, is to take over from him as Chairman of both Supervisory Boards. In recognition and deep appreciation of his long decades of accomplishment and invaluable work on behalf of Fresenius, Dr. Krick shall be named Honorary Chairman of both Supervisory Boards.

Klaus-Peter Müller (76) will be stepping down from the Supervisory Board of Fresenius Management SE at the end of his term in May 2021. At the listed Fresenius SE & Co. KGaA, Klaus-Peter Müller will stand for reelection to the Supervisory Board at the Annual General Meeting in May with the aim of chairing the Audit Committee for a further year.

Foscarnet Sodium Injection is now available in the United States, expanding the company’s anti-viral portfolio. The drug is used in the treatment of conditions associated with immunocompromised patients.

Fresenius has once again improved in this year's CDP ranking (formerly "Carbon Disclosure Project"). With a ranking in the second highest category B, Fresenius is one of the leading companies in the health care sector, both in Europe and globally. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 515 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

Acetaminophen injection is now available in the United States in ready-to-administer freeflex^® bags, expanding the company’s anesthesia and analgesia portfolio. The drug is used in the hospital setting for pain management and fever reduction.

Icatibant injection, an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema in adults, expands the company’s generic drug portfolio. Icatibant Injection is supplied as a prefilled, single-use syringe that is self-administered subcutaneously at the patient’s home or doctor’s office. In conjunction with launching its first specialty IV drug in the U.S., Fresenius Kabi is also launching KabiCare in the U.S., a comprehensive patient support program with case managers, co-pay assistance programs, injection training, and a patient assistance program.

Fresenius Helios has started publishing daily figures on the occupancy rate for intensive care beds in its 86 German hospitals. The website of each hospital will report the number of COVID-19 patients in the hospital’s regular and intensive care wards. It will also publish figures from the Robert Koch Institute, Germany’s national health agency, on the number of new infections in the surrounding region. Helios’ goal is to increase transparency and facilitate a data-based assessment of the pandemic at the local level. Helios Germany currently has a total of 1,300 intensive care beds across the country and could add an additional 1,000 on short notice, in the event of a sharp increase in COVID-19 hospitalizations.

• Wolfgang Kirsch nominated to become Chairman of Supervisory Board at close of Annual General Meeting in May 2021
• Dr. Gerd Krick to be named Honorary Chairman of Supervisory Board
• Michael Sen nominated to Supervisory Board, designated to take over from Klaus-Peter Müller as Chairman of Audit Committee
• Contract of CEO Stephan Sturm extended for additional five years

Wolfgang Kirsch, 65, a Member of the Supervisory Board of Fresenius Management SE since the start of this year, is to become the board’s Chairman. This was decided unanimously today by the Supervisory Board of Fresenius Management SE. At the Annual General Meeting in May 2021 he will also stand for election to the Supervisory Board of the publicly listed Fresenius SE & Co. KGaA, with the goal of assuming its chairmanship, as well. In both these posts, Wolfgang Kirsch is to succeed Dr. Gerd Krick, 82, who is not standing for reelection and will leave both Supervisory Boards when the term ends at the close of the Annual General Meeting.

In recognition and deep appreciation of his long decades of accomplishment and invaluable work on behalf of Fresenius, Dr. Krick shall be named Honorary Chairman of both Supervisory Boards.

Also at the Annual General Meeting in 2021, Michael Sen, 51, formerly a member of the Management Board of Siemens AG, will stand for election as a Member of the Supervisory Boards of Fresenius Management SE and Fresenius SE & Co. KGaA with the goal of taking over as Chairman of the Audit Committee. Klaus-Peter Müller, 76, will be stepping down from the Supervisory Boards at the end of his term.

The Supervisory Board of Fresenius Management SE also decided unanimously today to appoint Stephan Sturm, 57, to an additional five years as Chief Executive Officer of Fresenius. Stephan Sturm has been CEO of Fresenius since July 1, 2016, having previously served 11 and a half years as the company’s Chief Financial Officer.

Dr. Krick has held top positions at Fresenius for 45 years, ever since joining the former Dr. E. Fresenius KG as Managing Director for research & development, production and technology in 1975. This was the beginning of a hugely successful period in which Dr. Krick, who holds a doctorate degree in mechanical engineering, played a leading role in developing the company’s first dialyzers and balanced dialysis machines, and helped make dialysis-related activities a core business of Fresenius. These opened the way for the impressive growth achieved by the company, which he steadily drove forward as CEO between 1992 and 2003 and since then as Chairman of the Supervisory Board of Fresenius AG, now Fresenius SE & Co. KGaA.

The founding of both Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, and of Fresenius Kabi bear Dr. Krick’s signature. Fresenius’ entry into the hospital business, today under Fresenius Helios, and the acquisition of VAMED AG were further important strategic steps that were undertaken by Dr. Krick. Since May 2010, he has also served as Chairman of the Supervisory Board of Fresenius Management SE, following its establishment as part of the company’s change of legal form.

Dr. Gerd Krick said: “I feel great joy when I see the very impressive development of this unique company, to which I have had the privilege of contributing. I am grateful for the years-long teamwork with countless dedicated and talented people at Fresenius, and what we built together: A healthcare group of global importance. Through my role as Honorary Chairman of the Supervisory Board, I will remain closely connected with Fresenius.”

“Fresenius is very well equipped for the future, and it remains in the best of hands,” Dr. Krick continued. “With Wolfgang Kirsch, with whom I have worked closely and very trustfully since the start of this year, a very experienced expert, particularly in financial matters, will be succeeding me as Chairman of both of our Supervisory Boards. And with Stephan Sturm we have at the head of our Management Board an executive who has been central to designing and executing the strategy that has brought continued growth over many years, and who enjoys the complete confidence of the Supervisory Board. Together with his Management Board colleagues, he will continue to pursue the successful course Fresenius has set. In the name of the Supervisory Board, I want to thank my close associate and companion of many years, Klaus-Peter Müller, for his tireless efforts and his many important contributions to our company’s success.”  

Wolfgang Kirsch, the newly designated Chairman of the Supervisory Board, has been a Member of the Supervisory Board of Fresenius Management SE since the start of 2020, and was for many years an advisor to the Else Kröner-Fresenius Foundation. He also holds positions in the Würth Group and on the board of AGCO Corporation, of Atlanta. After joining the Management Board of DZ BANK AG in Frankfurt in 2002, he served as Chief Executive Officer from September 2006 to December 2018. The August 2016 merger of DZ BANK and WGZ BANK, to form the current DZ BANK, was carried out under Wolfgang Kirsch’s leadership. He began his career in 1975 as a trainee at Deutsche Bank before commencing studies in business administration at the University of Cologne. After graduating in 1981, Wolfgang Kirsch continued at Deutsche Bank, where he held a series of management positions through 2002, including in corporate and investment banking.

Klaus-Peter Müller has been a Member of the Supervisory Board of Fresenius SE (today Fresenius SE & Co. KGaA) since 2008 and is Chairman of the Audit Committee. Since 2010, he has also belonged to the Supervisory Board of Fresenius Management SE. A highly regarded financial expert, Klaus-Peter Müller worked at Commerzbank AG from 1966 to 2008 and served from 2001 to 2008 as Chief Executive Officer.

Michael Sen was a member of the Management Board of Siemens AG, where he was responsible for the company’s healthcare and energy businesses, from April 2017 to March 2020. Previously, from 2015 to 2017, he held the position of Chief Financial Officer at E.ON SE. Michael Sen began his career at Siemens in Berlin, where he completed an apprenticeship before studying business administration at the Technical University in Munich. After completing his studies, starting in 1996 he took on a range of projects and management responsibilities at Siemens, and from 2008 was Chief Financial Officer in the company’s Healthcare division before moving to E.ON.

As part of its reporting on quality standards, Fresenius Helios is publishing data on the length of patient stays, patient security and antibiotic use in the company’s German hospitals for the first time. Data from every Helios hospital is compiled in a total of 46 quality categories, including the frequency of surgical interventions and their results, and then published annually. The comparing of different hospitals’ statistics through the Quality Medicine Initiative yields specific, concrete improvements that can be implemented in day-to-day hospital operations. The initiative, which was jointly founded by Fresenius Helios, now includes more than 400 hospitals in Germany and Switzerland.